Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality

    Endah Lestari Endah Lestari, Nur Fitriani Nur Fitriani
    Image
    Studysummary The literature review concluded that while 5α-reductase inhibitors hold promise for managing prostate cancer, they raise significant safety concerns regarding their association with high-grade tumors and mortality, highlighting the need for careful consideration in their clinical use.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →